An analytical method was developed for the determination in urine of 2 metabolites of diazinon: 6-methyl-2-(1-methylethyl)-4(1H)-pyrimidinone (G-27550) and 2-(1-hydroxy-1-methylethyl)-6-methyl-4(1H)-pyrimidinone (GS-31144). Two of the urine sample preparation procedures presented rely on gas chromatography/mass selective detection (GC/MSD) in the selected ion monitoring mode for determination of G-27550. For fast sample preparation and a limit of quantitation (LOQ) of 1.0 ppb, urine samples were purified by using ENV+ solid-phase extraction (SPE) columns. For analyte confirmation at an LOQ of 0.50 ppb, classical liquid/liquid partitioning was used before further purification in a silica SPE column. An SPE sample preparation procedure and liquid chromatography/electrospray ionization/mass spectrometry/mass spectrometry (LC/ESI/MS/MS) were used for both G-27550 and GS-31144. The limit of detection was 0.01 ng for G-27550 with GC/MSD, and 0.016 ng when LC/ESI/MS/MS was used for both G-27550 and GS-31144. The LOQ was 0.50 ppb for G-27550 when GC/MSD and the partitioning/SPE sample preparation procedure were used, and 1.0 ppb for the SPE only sample preparation procedure. The LOQ was 1.0 ppb for both analytes when LC/ESI/MS/MS was used.
D
iazinon is an organophosphorus insecticide manufactured and formulated by several agricultural chemical companies and sold under various trademarks. It is most often used to control certain insects and mites on fruits, vegetables, field crops, lawns, and ornamentals. It metabolizes in plants and animals and undergoes environmental degradation to form the oxy-pyrimidinyl metabolites (G-27550 and GS-31144), the oxygen analog diazoxon, dialklythiophosphates, and dialkylphosphates (1, 2) . Their structures and metabolic pathways are shown in Figure 1 and their chemical names and CAS numbers are shown in Table 1 .
People who work as commercial applicators, mixers, or loaders face potential dermal and/or inhalation exposure when handling large quantities of the formulated active ingredient. To estimate this potential exposure, Novartis Crop Protection, Inc. is conducting worker exposure studies designed to provide information necessary to assess exposure and the use of metabolite data for biomonitoring "human exposure."
The analytical methodology most often used to assess organophosphorus pesticide exposure in humans involves the analysis of the dialkylphosphate and dialkylthiophosphate metabolites in urine (3) (4) (5) (6) (7) . However, these methods are not specific for diazinon exposure; the metabolism and environmental degradation of most organophosphorus compounds (including diazinon) can result in the presence of dialkylphosphates and/or dialkylthiophosphates in urine. Therefore, an analytical method for the analysis of G-27550 and/or GS-31144 in urine was needed to specifically assess diazinon exposure.
There is very little information in the literature regarding analysis of urine for G-27550 and GS-31144, and where reported, the limits of quantitation (LOQ) are much too high to be useful for worker exposure studies. In one report, gas chromatography (GC) and electrolytic conductivity detection (ECD) were used to analyze urine for derivatized G-27550 and GS-31144 at the 1 ppm concentration level (8) .
Thus, a good laboratory practice (GLP)-validated analytical method, acceptable to the U.S. Environmental Protection Agency, was needed to support worker exposure studies in which one or both oxy-pyrimidinyl metabolites of diazinon could be measured accurately and precisely. For the sample preparation procedures reported here, urine samples were fortified with G-27550 and GS-31144 from 0.50 to 100 ppb and subjected to one of 3 solid-phase extraction (SPE) sample preparation procedures (liquid/liquid partitioning was used in conjunction with one of the SPE procedures). For the final analysis, GC/mass selective detection (MSD) was used to determine only G-27550; for the final analysis of both com-pounds, liquid chromatography/electrospray ionization/mass spectrometry/mass spectrometry (LC/ESI/MS/MS) was used.
Experimental
Solvents and Reagents.-LC grade solvents methanol (A452-4), ethyl acetate (E195-4), dichloromethane (D143-4), and acetone (A949-4) and ACS grade acetic acid (A385-212), ammonium acetate (A639-500), anhydrous sodium sulfate (S415-212), and sodium chloride (S271-3) were all obtained from Fisher Scientific Co., Pittsburgh, PA. Standards.-Analytical standards of G-27550 (99%) and GS-31144 (98%) were obtained from Novartis Crop Protection, Inc., Greensboro, NC. Separate stock solutions were prepared at the 100 µg/mL concentration level in methanol (corrected for % purity).
Preparation of
For GC/MSD analyses, a 10.0 µg/mL G-27550 standard was prepared by diluting 10 mL stock solution to 100 mL in acetone. Serial dilutions were made of the 10.0 µg/mL standard to produce fortification and instrumental calibration standards in the range of 0.005-1.0 µg/mL (a calibration range of 0.010-2.0 ng injected for a 2 µL injection volume). For LC/ESI/MS/MS analyses, a 5.0 µg/mL mixed standard was prepared by combining aliquots of the G-27550 and GS-31144 100 µg/mL stock standards and diluting in water. Serial dilutions were made of this mixed standard in water to produce fortification and instrumental calibration standards in the range of 0.000625 to 1.0 µg/mL (0.016-25 ng injected based on a 25 µL injection volume).
Sample Storage.-Urine samples to be analyzed for residues of G-27550 and GS-31144, such as those collected during worker exposure studies, should be stored frozen until analyzed. The results of a storage stability study indicated that G-27550 is stable in urine under freezer storage conditions (-20EC) for at least 1 year (Yokley and Cheung, unpublished data, 1998). The freezer storage stability of GS-31144 is not expected to be significantly different from that of G-27550 (data not available for verification). The control and fortified control urine samples used during the method validation were pooled donor samples collected from various members of the Product Safety Group, Novartis Crop Protection, Inc.
Sample Preparation Procedures for the GC/MSD Analysis of G-27550
Two sample preparation procedures were used. Sample preparation procedure 2 (SPE only) required only about 3 h to prepare a set of 8-10 samples for analysis. However, residues at the 0.50-1.0 ppb concentration level could not always be confirmed because of qualifier ion interferences. Sample preparation procedure 1 (partitioning/SPE) was used when residues were detected in the 0.50-1.0 ppb concentration range and confirmatory evidence was required. This procedure was more labor-intensive, requiring about 6 h to prepare 8-10 samples for analysis. Identical GC/MSD operating parameters were used for the analyses regardless of the sample preparation procedure used.
In sample preparation procedure 1, a 25 mL aliquot of a well-mixed urine sample was transferred to a 50 mL Erlenmeyer flask. Control urine samples were fortified at this time. Sodium chloride (2 g) was added, mixed with the urine sample, and transferred to a 125 mL separatory funnel. The sample was partitioned with 50 mL ethyl acetate. After phase separation, the organic phase was transferred to a 250 mL flat-bottom flask and the urine sample was partitioned 3 more times, each with 25 mL portions of ethyl acetate. The 4 ethyl acetate fractions were pooled and dried by passing through a 20 g bed of anhydrous sodium sulfate (pre-rinsed with 40 mL ethyl acetate) contained in a carbon filter tube. The dried organic fraction was reduced in volume to <5 mL by rotary evaporation at a water bath temperature of 30-35EC. This fraction was then loaded onto a silica SPE column (preconditioned with 5 mL methanol and then 5 mL ethyl acetate) under gravity. The column was washed with 8 mL ethyl acetate (discarded), and the analyte was eluted with 10 mL methanol and collected in a 15 mL test tube. The collected methanol fraction was concentrated to near dryness at a water bath temperature of 30-35°C using a gentle stream of dry nitrogen. Acetone (5 mL) was added, and the sample was concentrated just to dryness, followed by reconstitution in 1 mL acetone or other appropriate final fraction volume, depending on the fortification or expected concentration level for final analysis using GC/MSD.
In sample preparation procedure 2, a 25 mL aliquot of a well-mixed urine sample was transferred to a 50 mL concentration tube. Control urine samples were fortified at this time. A 10 mL volume of 0.10M ammonium acetate buffer was added and thoroughly mixed with the urine sample. A 200 mg ISOLUTE ENV+ SPE column was preconditioned with 5 mL methanol; 5 mL 0.10M ammonium acetate buffer was added before the column was loaded with the urine sample. Each elution was performed under gravity. The concentration tube previously containing the urine sample was rinsed with 5 mL 0.010M ammonium acetate buffer, which was then added to the SPE column. After the load volume reached the top of the SPE sorbent, the column was washed with 5 mL 0.10M ammonium acetate buffer. Full vacuum was applied for ca 25 min to completely dry the SPE column. The analytes were then eluted with three 3 mL portions of dichloromethane/ethyl acetate (50 + 50, v/v) and collected in a 15 mL test tube. The sample was concentrated to near dryness at a water bath temperature of 30-35°C using a gentle stream of dry nitrogen. Acetone (5 mL) was added and the sample was concentrated just to dryness followed by reconstitution in 1 mL acetone or other appropriate final fraction volume, depending on the fortification or expected concentration level for final analysis using GC/MSD.
Sample Preparation for LC/ESI/MS/MS Analysis of G-27550 and GS-31144
In the sample preparation procedure used for the analysis of both compounds, a 25 mL aliquot portion of a well-mixed urine sample was transferred to a 50 mL concentration tube. Control urine samples were fortified at this time. Two urine control samples were prepared for each analytical set: one was used as a control and the other was fortified after the sample preparation procedure. A 10 mL volume of 0.10M ammonium acetate buffer was added and thoroughly mixed with the urine sample. A Varian Bond Elut PPL SPE column (200 mg/3 mL) was preconditioned with 3 mL methanol and 3 mL ammonium acetate buffer solution. The urine sample was loaded onto the SPE column and allowed to flow through the column under gravity initially; then slight vacuum was applied. The concentration tube originally containing the urine samples was rinsed with 5 mL water, which was then added to the sample load. When sample loading was completed, the column was dried for 20 min under vacuum. The analytes were eluted using three 3 mL portions of ethyl acetate and collected in a 15 mL test tube. The ethyl acetate fraction was reduced just to dryness using rotary evaporation and the residue was reconsti- An Agilent Series 1100 LC system equipped with a 4.6 × 150 mm Zorbax SB-CN column (5 µm particle size) was used for the separation. Switching valves were used to route 100% of the column effluent to waste until about 2 min before elution of the first analyte through about 1 min after elution of the second analyte, wherein the column effluent was directed to the ESI source. In addition, a 1:5 split was used during the time the column effluent was routed to the mass spectrometer (i.e., 80% of the column flow was routed to waste and 20% to the mass spectrometer). The mobile phase gradient used was: Mobile phase A: 4.9% methanol-95% water-0.10% formic acid; mobile phase B: 99.9% methanol-0.10% formic acid; gradient (time, %B): 0, 22; 4, 100; 12, 100; 14, 22. Flow rate, 300 µL/min; valve switching, 0 min to waste; 7.5 min to ESI; 11.5 min to waste. Rt: GS-31144, ca 9.4 min; G-27550, ca 10.1 min. Table 2 shows recovery data obtained for G-27550 at each fortification level when sample preparation procedure 1 (partitioning/SPE) was used. Overall, recoveries averaged 101.3% with a standard deviation of 21.7%. Figure 3 shows representative SIM chromatograms of 0.010 ng injected standard (lowest concentration of standard injected and used to construct the calibration plot), control, and 0.50 ppb procedural recovery sample for G-27550 when sample preparation procedure 1 was used. A target ion peak appeared at the retention time (Rt) of the analyte in the control, but it was <0.50 ppb. The Q1 and Q2 ions were not detected in the control sample; thus, they can be used for confirmatory purposes. However, the Q2 ion was barely discernible in the 0.50 ppb recovery sample because of its relatively low abundance (about 15%) compared to the target ion. It can be used for confirmatory purposes, but it is not as consistent or as reliable as the Q1 ion for confirmation. The limit for analyte confirmation was set at ± 20% of the Qualifier/Target ion ratio as measured and compared with an analytical standard. Target ion peaks (m/z 137) detected in the control samples at the analyte Rt were always subtracted from the target ion peaks detected in the fortified samples for calculation of % recovery even if the qualifier ions (m/z 152 and 124) were absent. Q1 and Q2 in Figure 3 refer to the qualifier ions used for confirmatory purposes and should not be confused with the Q1 and Q2 designations used for quadrupoles in MS/MS terminology. Table 3 shows recovery data for G-27550 at each fortification level when sample preparation procedure 2 (SPE only) was used. Overall, recoveries averaged 100.8% with a standard deviation of 17.8%. Recovery data obtained at the 0.50 ppb fortification level were also acceptable, but sample matrix interferences hindered reliable confirmation of the analyte's identity at a concentration of 0.50 to just under 1.0 ppb because of Q1 and Q2 ion matrix interferences. Because consistent confirmation was obtained at the 1.0 ppb concentration level and greater, the method LOQ was 1.0 ppb when sample preparation procedure 2 was used. The DB-Wax column provided excellent peak shape and Rt reproducibility for G-27550 but not for GS-31144. Good linearity was obtained for G-27550 for all the method validation sets as demonstrated by consistent correlation coefficients $0.99. Although the chromatography obtained for GS-31144 on the DB-Wax column was insufficient for quantitative analysis, it was still better than that obtained when other capillary columns of different polarity (e.g., DB-5 and DB-1701) were used with a variety of operating parameters. This analyte would probably require derivatization before GC analysis.
Results and Discussion

GC/MSD Analyses
The limit of detection of the method, defined as the lowest concentration of standard injected and used for construction of the calibration plot, was 0.010 ng. The signal-to-noise ratio at this injected concentration level was >10. The LOQ of the method, defined as the lowest procedural recovery sample concentration tested in the validation, was 0.50 ppb for G-27550 when sample preparation procedure 1 was used. However, sample preparation procedure 2 is recommended for analysis of urine samples because it is much less labor-intensive. If residues are detected at concentration levels <1.0 ppb and analyte confirmatory evidence is required at the 0.50 ppb concentration level, then sample preparation procedure 1 must be used. Table 4 shows recovery data for G-27550 and GS-31144 at the 1.0, 5.0, and 10 ppb fortification levels as a function of increasing final fraction volumes. The original final fraction volume was 1.0 mL. A portion of this sample was diluted 1:2 with 30% methanol + 70% water to mimic a final fraction volume of 2.0 mL, and analyzed. Subsequent dilutions (1:4, 1:8, and 1:12) were made to simulate final fraction volumes of 4.0, 8.0, and 12 mL. Two control samples were subjected to the SPE sample preparation procedure: one was used as a control, and the other was fortified with both analytes at the 1.0 ppb concentration level just before analysis to evaluate potential matrix effects. Table 4 shows that the mean procedural recoveries for G-27550 and GS-31144 were only 34 and 44%, respectively, when the final fraction volume was 1.0 mL. Recoveries obtained for the control sample fortified after the sample preparation procedure were similar (34 and 48%, respectively). The recovery results for this sample should be about 100%; thus, a signal reduction of 66% for G-27550 and 56% for GS-31144 occurred as a result of ion suppression. This phenomenon was recently reported and described in the literature (9-12; Yokley and Cheung, oral presentation, LC/MS Symposium, 50th SERMACS, 1998) as was ion enhancement (Yokley et al., oral presentation, 34th Florida Pesticide Residue Workshop, 1997). Ion suppression (or enhancement) is characterized by a decrease (or increase) of the analyte signal in the presence of matrix components as compared with that in the absence of matrix components (i.e., injections of standards). The exact nature of ion suppression is not fully understood but it may be a result of gas-phase proton transfer reactions in the high pressure region of the ESI source between the analyte (M + 1) + ions and those co-eluting matrix components that are more basic. In addition, there may be significant competition between the analyte and other co-eluting matrix components for the limited number of surface excess charge sites during electrospray droplet formation, which is dependent on the nature of the matrix components and their concentrations. Ion enhancement may be due to an increased efficiency of analyte transport into the mass spectrometer as a result of chromatographic focusing (band narrowing) and/or improved efficiency in analyte ion formation resulting from the presence of co-eluting matrix components that are more acidic than the analyte. Possible solutions to ion suppression (or enhancement) include increasing the k′ value of the liquid chromatographic separation, using additional sample preparation procedures (e.g., SPE, liquid/liquid partitioning), column switching techniques, modifications of the sample preparation procedure, and final analytical measurement to allow the use of smaller initial sample sizes. The goal in all these procedures is to minimize or eliminate those sample matrix components that co-elute and interfere (by suppression or enhancement) with the ionization of the analyte and/or its transport into the mass spectrometer.
LC/ESI/MS/MS Analyses
Matrix Effects Using LC/ESI/MS/MS
As shown in Table 4 , the % recoveries obtained for G-27550 and GS-31144 were significantly improved by increasing the final fraction volume and thus reducing the quantity of urine sample matrix components injected. Acceptable recoveries (70-120%) were obtained with a final fraction volume of 4.0 mL for GS-31144, but recoveries for G-27550 at this volume were still overall <70%. The ion suppression effect was more severe in this case for the analyte with the longer Rt, probably because of the quantity and chemical nature of the sample matrix components co-eluting with the more suppressed analyte. However, molecular structural differences between G-27550 (mono-OH) and GS-31144 (di-OH) may have contributed to the magnitude of ion suppression under the urine sample preparation and instrumental operating parameters used. A final fraction volume of 12 mL is sufficient to obtain acceptable recoveries for both G-27550 and GS-31144 at all fortification levels studied. Figure 4 shows representative multiple reaction monitoring (MRM) chromatograms obtained for a 0.016 ng injected standard, control, and a control fortified with 1.0 ppb of G-27550 and GS-31144 before sample preparation. These chromatograms were acquired during analysis of the 12 mL final fraction volume samples. Note the small control peak at the Rt of GS-31144 in Figure 4 (B). Most of the controls did not contain this peak, but it is still 33 times less intense than the 1.0 ppb procedural recovery sample [ Figure 4 (C)] as shown by peak responses 2631 for the GS-31144 recovery sample and 78 for the control peak. Also note the large peak that elutes prior to G-27550 in Figure 4 (B and C). The y-axes in Figure 4 (B and C) are scaled on the large, early eluting peak and not on G-27550. Thus, the response factor for G-27550 appears to be less than that of GS-31144 when in fact its response was greater. The components comprising the tail of this peak may have contributed to the ion suppression when smaller final fraction volumes were used before analysis. Increasing the Rt of the analytes by adjusting the mobile phase gradient is also a means of reducing ion suppression. In this case, near baseline resolution of G-27550 from the large tailing sample matrix peak was required.
Urine samples were also analyzed after fortification at the 0.50 ppb concentration level for both analytes using a final fraction volume of 10 mL. The recoveries were 70% for G-27550 and 83% for GS-31144. The recoveries for the control sample fortified after sample preparation were identical to those for the control samples fortified before sample preparation, indicating that ion suppression accounted for the respective 30 and 17% losses in recovery. Thus, the 0.50 ppb recoveries for G-27550 and GS-31144 (70 and 83%) using 10 mL as the final fraction volume resemble the 1.0 ppb recoveries of 68 and 84% (Table 4 ) with 4.0 mL as the final fraction volume. This demonstrates that the absolute concentration of the matrix component(s) in the final fraction is important in determining when ion suppression starts becoming a problem. Further work is required to consistently obtain acceptable recoveries at the 0.50 ppb fortification level for G-27550.
Urine is a complex sample matrix consisting of various amino acids, peptides, proteins, urea, uric acid, creatinine, creatine, sugars, lipids and fats, salts, and numerous other components. Its pH is typically between 4.8 and 7.6, averaging 6.0, and its specific gravity is typically between 1.010 and 1.025 (13) . Bond Elut PPL, a styrene divinyl benzene (SDVB) based polymeric SPE column, and ISOLUTE ENV+, a hyper cross-linked SDVB co-polymeric based SPE column, were used for urine purification. Both columns are applicable to the extraction of highly polar species from water and biological fluids and tend to have higher capacities than traditional silica-based columns such as C 8 and C 18 . Silica SPE is applicable to the extraction of polar species from ethyl acetate after classical liquid/liquid partitioning. Some urine components are structurally similar to the oxy-pyrimidinyl metabolites of diazinon, and the goal of using the sample preparation procedures described here is to remove as many urine sample matrix components as possible before analysis of the final fraction. However, ion suppression during LC/ESI/MS/MS analysis indicates that one or more urine sample components survived the sample purification procedure, and these can adversely affect the recovery results.
Dialkylphosphate and dialkylthiophosphate metabolites formed during diazinon metabolism are not likely to survive the SPE sample preparation procedures; they also require derivatization before GC analysis. These characteristics and the high degree of selectivity associated with MS/MS analysis make it highly improbable that these compounds could interfere during the analysis of urine for G-27550 and GS-31144 by either instrumental technique. The concentration of the metabolite diazoxon found in rat urine (0.14%) is significantly less than the concentrations of G-27550 (38.2%) and GS-31144 (17.3%) found in rat urine after intragastric dosing of rats with 14 C-labeled diazinon (Capps et al., unpublished data, 1989). Thus, the expected concentrations of these metabolites in human urine and the high degree of instrumentation selectivity in the final measurement virtually eliminates any possibility that diazoxon could interfere with the analysis of urine for the oxy-pyrimidinyl metabolites. Diazoxon metabolizes rapidly in high aqueous environments to form G-27550 and GS-31144.
Conclusions
Urine sample preparation procedures 1 and 2 followed by GC/MSD analysis comprise a valid, precise, and accurate GLP-validated method for the determination of G-27550 in urine. The method can be used as a biomonitoring tool to evaluate potential diazinon exposure in humans. Sample preparation procedure 2 is much less labor-intensive than procedure 1 and is the recommended procedure for a first-time analysis of urine samples (i.e., as a screening tool). Sample preparation procedure 1 is recommended only when confirmatory evidence is required for residues in the 0.50 to 1.0 ppb concentration range or when the concentration of the residue in the sample is expected to be <1.0 ppb (e.g., in known pre-exposure urine samples).
LC/ESI/MS/MS can also be used with an LOQ of 1.0 ppb if data are required for both oxy-pyrimidinyl metabolites. The LC/ESI/MS/MS method presented here has not been validated under GLP guidelines. Matrix effects were significantly reduced in this study by increasing the final fraction volumes to decrease the quantity of urine component(s) injected and by using longer analyte retention times to minimize the quantity of co-eluting sample matrix component(s). The potential for matrix effects must be considered when LC/ESI/MS/MS is used to analyze complex sample matrixes.
